- Page 1 and 2:
BIBLIOGRAFIA SUI DANNI DA VACCINI A
- Page 3 and 4:
Alter HJ, Scanlon RT, Schechter GP.
- Page 5 and 6:
Cherry, JD, et al. A Clinical and S
- Page 7 and 8:
Kazarian EL, Gager WE. Optic neurit
- Page 9 and 10:
Coplan J. Seizures following immuni
- Page 11 and 12:
Ipp MM, Gold R, Greenberg S, Goldba
- Page 13 and 14:
Int J Ped Oto, Feb 1998, 43(1):73
- Page 15 and 16:
Mashikian MV, Stollerman GH. Vaccin
- Page 17 and 18:
Wu T, Wang SL, Xiang YZ. Study on t
- Page 19 and 20:
Prevots DR, Ciofi degli Atti ML, Sa
- Page 21 and 22:
Del Giudice G, Pizza M, Rappuoli R.
- Page 23 and 24:
Huber S, Kappos L, Fuhr P, Wetzel S
- Page 25 and 26:
Ngui SL, Hallet R, Teo CG. Natural
- Page 27 and 28:
Thomson J, Hilditch A, Pirkis J, Du
- Page 29 and 30:
Belloni C, Pistorio A, Tinelli C, K
- Page 31 and 32:
DanielRibeiro CT. Is there a role
- Page 33 and 34:
Gallup, R. The MMR question [letter
- Page 35 and 36:
Hull BP, McIntyre PB. A reevaluat
- Page 37 and 38:
Lieu TA, Ray GT, Black SB, Butler J
- Page 39 and 40:
Mulholland K. Evaluation of vaccine
- Page 41 and 42:
Rudolph, K. M., Parkinson, A. J., R
- Page 43 and 44:
Taylor JA, Newman RD. Parental atti
- Page 45 and 46:
Bonaccorsi G, Papini D, Bonanni P,
- Page 47 and 48:
Hanna, J. N., Young, D. M., Brookes
- Page 49 and 50:
Mortimer, E. A. Jr, Ball, R., Ball,
- Page 51 and 52:
Taranger, J., Trollfors, B., Bergfo
- Page 53 and 54:
Christensen, L. S., Scholler, S., S
- Page 55 and 56:
Khanal, P. Nepal's Childhood Mortal
- Page 57 and 58:
Poland GA, Jacobson RM, Vierkant RA
- Page 59 and 60:
Vyse, A. J., Gay, N. J., White, J.
- Page 61 and 62:
Brodkin, H. Economic Analysis of In
- Page 63 and 64:
Freed, G. L., Davis, M. M., and Cla
- Page 65 and 66:
Karlsen, T. H.; Sommerfelt, H.; Klo
- Page 67 and 68:
NascimentoCarvalho, C. M.; Moreno
- Page 69 and 70:
Skegg, D. C. Autism and MeaslesMu
- Page 71 and 72:
Wharton, M., Strikas, R. A., Harpaz
- Page 73 and 74:
Boyce, T. G.; Weaver, A. L.; St Sau
- Page 75 and 76:
D'Heilly, S. J.; Nichol, K. L. Work
- Page 77 and 78:
Guy, B.; Chanthavanich, P.; Gimenez
- Page 79 and 80:
Koca, R.; Altinyazar, H. C.; Numano
- Page 81 and 82:
Modlin, J. F. Poliomyelitis in the
- Page 83 and 84:
Roost, H. P.; Gassner, M.; Grize, L
- Page 85 and 86:
Vazquez, M.; LaRussa, P. S.; Gersho
- Page 87 and 88:
Beaujean, D. J.; Verweij, M. F.; va
- Page 89 and 90:
Desjeux, G.; GaloisyGuibal, L.; C
- Page 91 and 92:
Gust, D.; Brown, C.; Sheedy, K.; Hi
- Page 93 and 94:
Koch, D.; Thompson, L.; Swart, B. L
- Page 95 and 96:
Newport, M. J.; Goetghebuer, T.; Ma
- Page 97 and 98:
Satcher, D. Adult Immunization Disp
- Page 99 and 100:
Timmermans, D. R.; Henneman, L.; Hi
- Page 101 and 102:
Aaby, P.; Jensen, H.; Walraven, G.
- Page 103 and 104:
Carrat, F.; Lavenu, A.; Cauchemez,
- Page 105 and 106:
Emanuel, E. J.; Wertheimer, A. Publ
- Page 107 and 108:
Halperin, S. A.; Sweet, L.; Baxenda
- Page 109 and 110:
Klote, M. M.; Engler, R. J.; Martin
- Page 111 and 112:
Mitka, M. Age Range Widens for Pert
- Page 113 and 114:
Pool, V.; Iskander, J. Safety of In
- Page 115 and 116:
Skowronski, D. M.; Woolcott, J. C.;
- Page 117 and 118:
Vu, D. M.; Kelly, D.; Heath, P. T.;
- Page 119 and 120:
Approved: New Requirement Allowing
- Page 121 and 122:
Caldwell, S. J.; Hayney, M. S. Prop
- Page 123 and 124:
Dempsey, A. F. Vaccination Against
- Page 125 and 126:
Galvani, A. P.; Reluga, T. C.; Chap
- Page 127 and 128:
Influenza Vaccination Coverage Amon
- Page 129 and 130:
Lawrence, S. J.; Lottenbach, K. R.;
- Page 131 and 132:
Monath, T. P. Yellow Fever As an En
- Page 133 and 134:
Patrick, D. Prevention Strategies:
- Page 135 and 136:
Scheiblhofer, S.; Weiss, R.; Thalha
- Page 137 and 138: Takada, T.; Yamashita, T.; Sato, M.
- Page 139 and 140: Winston, C. A.; Mims, A. D.; Leathe
- Page 141 and 142: Bechtol, Z. Launching a Community
- Page 143 and 144: Chumakov, K.; Ehrenfeld, E. Vaccine
- Page 145 and 146: Dylag, A. M.; Shah, S. I. Administr
- Page 147 and 148: GomezdeLeon, P.; DiazGarcia,
- Page 149 and 150: Jackson, L. A.; Starkovich, P.; Dun
- Page 151 and 152: Kusuhara, K.; Ohga, S.; Hoshina, T.
- Page 153 and 154: Madjid, M. Acute Infections, Vaccin
- Page 155 and 156: Naghipour, M.; Nakagomi, T.; Nakago
- Page 157 and 158: Pool, R.; Mushi, A.; Armstrong, Sch
- Page 159 and 160: Savidan, E.; Chevat, C.; Marsh, G.
- Page 161 and 162: Strauman, T. J.; Coe, C. L.; McCrud
- Page 163 and 164: Vien, N. C.; Feroldi, E.; Lang, J.
- Page 165 and 166: Akmatov, M. K.; Mikolajczyk, R. T.;
- Page 167 and 168: Braillon, A. A New French Paradox:
- Page 169 and 170: Daley, M. F.; Curtis, C. R.; Pyrzan
- Page 171 and 172: Flu Campaign Receives Excellence Aw
- Page 173 and 174: Holvast, A.; van, Assen S.; de, Haa
- Page 175 and 176: Kisakye, A.; Makumbi, I.; Nansera,
- Page 177 and 178: Makidon, P. E.; Nigavekar, S. S.; B
- Page 179 and 180: Niu, M.; Ball, R. Adverse Events Af
- Page 181 and 182: Primus, L. Improving Influenza Vacc
- Page 183 and 184: Schwartz, B.; Orenstein, W. A. Prio
- Page 185 and 186: Tharmaphornpilas, P.; Yoocharean, P
- Page 187: Weiskopf, D.; Weinberger, B.; Grube